- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04390282
Secondary Prevention and Application-based Lifestyle Support for Patients With Intermittent Claudication (PRESIC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A randomized controlled pilot trial will be used to test the application-based support systems Lifepod®PAD that are developed in collaboration with Cross Technology Solutions based on results from our systematic review and previous research testing the Lifepod® system in patients with myocardial infarction.
Sample Approximately 60 patients with intermittent claudication diagnosed at the Department of vascular diseases at Skåne University hospital will be invited to participate. The participants should have access to a smartphone or tablet. For the randomization, envelopes will be prepared by a member of the research group and then mixed by another member of the group. After receiving informed consent, the participants are randomized by drawing one of the sealed envelopes with the information in which group they are included. The trial will have two arms; one group will test Lifepod®PAD (n=30) for three months and one control group (n=30) will receive secondary prevention as usual.
Data collection All participants will be invited to a separate appointment at the vascular open clinic at baseline and after three months and measured regarding weight, blood pressure, ABPI, six minutes walking test and pain. To calculate the estimate 10-year risk of manifesting clinical cardiovascular disease, the Framingham Risk Score will be used. Further, a questionnaire will be answered at baseline and after three months containing the instruments, VascuQoL-6, Health Education Impact Questionnaire (hei-Q) and Medication Adherence Report Scale-5.
Patients randomized to Lifepod®PAD will get access and be introduced to the Lifepod®PAD support system software. Patients in the control group will receive usual care meaning advice about lifestyle changes and medication from the physician at the visit in the vascular open clinic.
After completing the intervention, a random number of patients who have tested Lifepod®PAD will be invited to take part in focus group interviews to discuss their experiences of using the devices. The interviews will be analyzed by thematic content analysis.
The intervention Lifepod®PAD is a web-based application designed to support adherence to lifestyle advice and medication and is built as a two-side system. One side is the patient interface, the web-based application, accessible through a smartphone or tablet. The patients can log information about their lifestyle, symptoms and medication and review their data in relation to recommended targets. They get positive feedback, recommendations about healthy behaviours and receive notifications as short messages depending on their individual health status. The other side is the medical interface managed by the health care professionals. All information the patient is reporting into the app can be accessed by the treating nurse and the system ranks the patients, thus gives high priority to patients who have the greatest needs.
Analysis Primary outcome will be pain free walking distance according to six minutes walking test at baseline and after three months. Secondary outcomes are quality of life, illness perception, self-efficacy, adherence to medical treatment, blood pressure and ABPI. Acceptability, delivery of the intervention, expected sample size and effect size, procedure of randomization and follow-ups will be further evaluated.
Descriptive statistics will be used to describe the study sample. T-tests will be used to compare groups and chi-square tests will be used to study differences in proportions. Effect size will be calculated to estimate the magnitude of the potential effects and constitute a base for power calculation and sample size in a full-size RCT. The outcome will be used to design a main multicenter randomized trial Ethical considerations Verbal and written information about the purpose of the studies will be given and a written informed consent will be obtained in all studies. Additionally, they will be informed that participating is voluntary and the can withdraw at any time without providing any reason. Approval for the project are provided by the Swedish Regional Ethical Review Board (Dnr 2017/609)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Malmö, Sweden, 20506
- Christine Kumlien
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with intermittent claudication diagnosed at the Department of vascular diseases at Skåne University hospital.
The participants should have access to a smartphone or tablet and be able to speak and understand Swedish.
Exclusion Criteria:
- Patients with intermittent claudication who are considered for revascularization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Application-based support system Lifepod®PAD
Patients in the experimental group will be introduced to and use Lifepod®PAD, a web-based application designed to support adherence to lifestyle advice and medication for three months.
Lifepod®PAD is built as a two-side system.
One side is the patient interface, the web-based application, accessible through a smartphone or tablet.
The patients can log information about their lifestyle, symptoms and medication and review their data in relation to recommended targets.
They get positive feedback, recommendations about healthy behaviours and receive notifications as short messages depending on their individual health status.
The other side is the medical interface managed by the health care professionals.
All information the patient is reporting into the app can be accessed by the treating nurse and the system ranks the patients, thus gives high priority to patients who have the greatest needs.
|
All participants (experimental and control group) will be invited to a separate appointment at the vascular open clinic at baseline and after three months and measured regarding weight, blood pressure, Ankle Brachial Pressure Index, six minutes walking test and pain.
To calculate the estimate 10-year risk of manifesting clinical cardiovascular disease, the Framingham Risk Score will be used.
Further, a questionnaire will be answered at baseline and after three months containing the instruments, VascuQoL-6, Health Education Impact Questionnaire and Medication Adherence Report Scale-5.
Other Names:
|
No Intervention: Life style advice according to usual practice
Patients in the control group will receive usual care meaning advice about lifestyle changes and medication from the physician at the visit in the vascular open clinic.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain free walking distance
Time Frame: Change from baseline in pain free walking distance baseline at three months
|
Pain free walking distance will be measured by 6 minutes walking test.
|
Change from baseline in pain free walking distance baseline at three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life assessment
Time Frame: Change from baseline in Vascuqol 6 total score (min 6 max 24, higher total score means better quality of life) at three months
|
Measured by the quality of life questionnaire Vascuqol 6
|
Change from baseline in Vascuqol 6 total score (min 6 max 24, higher total score means better quality of life) at three months
|
Ankle brachial pressure index
Time Frame: Change from baseline in ankle brachial pressure index at three months
|
Index based on calculation of ankle pressure and systolic blood pressure
|
Change from baseline in ankle brachial pressure index at three months
|
Illness perception
Time Frame: Change from baseline in Illness Perception scale (Include three sections that each have a totalscore, a high totalscore means a personal understanding of illness) at three months
|
Measured by Illness Perception Questionnaire
|
Change from baseline in Illness Perception scale (Include three sections that each have a totalscore, a high totalscore means a personal understanding of illness) at three months
|
Medication adherence
Time Frame: Change from baseline in Medication Adherence Report Scale (min 5 max 25 in total score a higher total score indicates higher level of adherence) at three months
|
Measured by Medication Adherence Report Scale
|
Change from baseline in Medication Adherence Report Scale (min 5 max 25 in total score a higher total score indicates higher level of adherence) at three months
|
Self efficacy
Time Frame: Change from baseline in General Self- Efficacy Scale (min 10 max 40 in total score a higher total score indicates more self efficacy) at three months
|
Measured by General Self-Efficacy Scale
|
Change from baseline in General Self- Efficacy Scale (min 10 max 40 in total score a higher total score indicates more self efficacy) at three months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CKtrial2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vascular Diseases
-
Terumo Europe N.V.CompletedPeripheral Vascular Disease | Hemostasis | Vascular Closure | Endovascular ProcedureBelgium, France, Germany
-
University Hospital, MontpellierTerminated
-
AmgenCompletedChorioretinal Vascular DiseaseUnited States
-
Duke UniversityTerminatedRetinal Vascular DiseaseUnited States
-
Alvotech Swiss AGActive, not recruitingChorioretinal Vascular DiseaseGeorgia
-
University of California, IrvineUniversity of Oklahoma; US Department of Veterans Affairs; C. R. Bard; Long Beach...CompletedPeripheral Vascular Disease | Cardiac Catheterization | Vascular Access ComplicationsUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
Regeneron PharmaceuticalsCompletedChorioretinal Vascular DiseaseUnited States
-
Unity Health TorontoUnknownPeripheral Vascular Disease Patient
Clinical Trials on Application-based support system
-
Wings Health AGUniversity Hospital, Basel, SwitzerlandRecruitingProstate Cancer | Psychosocial StressorSwitzerland
-
MemorialCare Health SystemNot yet recruitingPreeclampsia | Preeclampsia Postpartum | Preeclampsia Severe | Preeclampsia Mild
-
Anhui Medical UniversityUnknown
-
Children's Hospital Medical Center, CincinnatiCompletedUlcerative Colitis, PediatricUnited States
-
Necmettin Erbakan UniversityCompletedPostpartum Depression | Postnatal Complication | Nurse's RoleTurkey
-
Wuerzburg University HospitalCharite University, Berlin, Germany; Goethe University; RWTH Aachen University; Technical University of Munich and other collaboratorsRecruitingSurgery | ASA Class III/IV Patients | Clinical Decision Support SystemsGermany
-
Sanko UniversityUniversity of GaziantepNot yet recruiting
-
Dokuz Eylul UniversityNot yet recruitingPost-Traumatic Stress Disorder (PTSD)
-
Donders Centre for NeuroscienceRecruitingStrokeFrance, Romania, Spain
-
Xijing HospitalUnknownStroke | Vertigo | Headache | Meningitis/Encephalitis